<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">ACS Cent Sci</journal-id>
    <journal-id journal-id-type="iso-abbrev">ACS Cent Sci</journal-id>
    <journal-id journal-id-type="publisher-id">oc</journal-id>
    <journal-id journal-id-type="coden">acscii</journal-id>
    <journal-title-group>
      <journal-title>ACS Central Science</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">2374-7943</issn>
    <issn pub-type="epub">2374-7951</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7318080</article-id>
    <article-id pub-id-type="doi">10.1021/acscentsci.0c00229</article-id>
    <article-categories>
      <subj-group>
        <subject>Research Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Deep Docking: A Deep Learning Platform for Augmentation
of Structure Based Drug Discovery</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Gentile</surname>
          <given-names>Francesco</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="notes3" ref-type="notes">#</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Agrawal</surname>
          <given-names>Vibudh</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="notes3" ref-type="notes">#</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Hsing</surname>
          <given-names>Michael</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <name>
          <surname>Ton</surname>
          <given-names>Anh-Tien</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <name>
          <surname>Ban</surname>
          <given-names>Fuqiang</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath6">
        <name>
          <surname>Norinder</surname>
          <given-names>Ulf</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">∇</xref>
        <xref rid="aff3" ref-type="aff">∥</xref>
      </contrib>
      <contrib contrib-type="author" id="ath7">
        <name>
          <surname>Gleave</surname>
          <given-names>Martin E.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath8">
        <name>
          <surname>Cherkasov</surname>
          <given-names>Artem</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Vancouver
Prostate Centre, <institution>University of British Columbia</institution>, Vancouver, British Columbia V6H3Z6, <country>Canada</country></aff>
      <aff id="aff2"><label>∇</label>Swetox,
Unit of Toxicology Sciences, <institution>Karolinska
Institutet</institution>, Forskargatan
20, SE-151 36 Södertalje, <country>Sweden</country></aff>
      <aff id="aff3"><label>∥</label>Department
of Computer and Systems Sciences, <institution>Stockholm
University</institution>, Box 7003, SE-164
07 Kista, <country>Sweden</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>E-mail: <email>acherkasov@prostatecentre.com</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>19</day>
      <month>05</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <day>24</day>
      <month>06</month>
      <year>2020</year>
    </pub-date>
    <volume>6</volume>
    <issue>6</issue>
    <fpage>939</fpage>
    <lpage>949</lpage>
    <history>
      <date date-type="received">
        <day>24</day>
        <month>02</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2020 American Chemical Society</copyright-statement>
      <copyright-year>2020</copyright-year>
      <copyright-holder>American Chemical Society</copyright-holder>
      <license>
        <license-p>This is an open access article published under an ACS AuthorChoice <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_0007" id="ab-tgr1"/>
      </p>
      <p>Drug
discovery is a rigorous process that requires billion dollars
of investments and decades of research to bring a molecule “from
bench to a bedside”. While virtual docking can significantly
accelerate the process of drug discovery, it ultimately lags the current
rate of expansion of chemical databases that already exceed billions
of molecular records. This recent surge of small molecules availability
presents great drug discovery opportunities, but also demands much
faster screening protocols. In order to address this challenge, we
herein introduce Deep Docking (<italic>DD</italic>), a novel deep
learning platform that is suitable for docking billions of molecular
structures in a rapid, yet accurate fashion. The <italic>DD</italic> approach utilizes quantitative structure–activity relationship
(QSAR) deep models trained on docking scores of subsets of a chemical
library to approximate the docking outcome for yet unprocessed entries
and, therefore, to remove unfavorable molecules in an iterative manner.
The use of <italic>DD</italic> methodology in conjunction with the
FRED docking program allowed rapid and accurate calculation of docking
scores for 1.36 billion molecules from the ZINC15 library against
12 prominent target proteins and demonstrated up to 100-fold data
reduction and 6000-fold enrichment of high scoring molecules (without
notable loss of favorably docked entities). The <italic>DD</italic> protocol can readily be used in conjunction with any docking program
and was made publicly available.</p>
    </abstract>
    <abstract abstract-type="short">
      <p>We developed
Deep Docking, a deep learning platform that
relies on quantitative structure−activity relationship models
trained with docking scores of small portions of ultralarge databases
to predict scores of remaining entries and, thus, to accelerate virtual
screening by 50 times.</p>
    </abstract>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>oc0c00229</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>oc0c00229</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Drug discovery is an
expensive and time-demanding process that
faces many challenges, including low hit discovery rates for high-throughput
screening, among many others.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> Methods of computer-aided
drug discovery (CADD) can significantly speed up the pace of such
screening and can drastically improve hit rates.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Molecular docking is routinely used to process virtual
libraries containing millions of molecular structures against a variety
of drug targets with known three-dimensional structures.</p>
    <p>Recent
advancements in automated synthesis and surge of available
chemicals represent great opportunities for virtual screening (VS)
approaches in general and for docking in particular, but also poses
entirely novel challenges. For instance, the widely used ZINC library
has grown from 700 000 entries in 2005<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> to over 1.3 billion constituent molecules in 2019,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> representing a remarkable 1000-fold increase. There is
still a global lack of experience in screening such libraries, and
the advantage of docking them versus smaller collections is still
matter of debate.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> However, few recently
published works seem to advocate for expanding VS to ultralarge chemical
libraries. In a recent groundbreaking study by Lyu et al,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> authors reported docking of 170 million make-on-demand
molecular structures, showing that VS of such databases enables the
discovery of highly potent inhibitors as well as novel chemical classes
that are not present in routinely screened in-stock libraries. Later,
other docking studies involving large collections of molecules led
to similar conclusions.<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup></p>
    <p>Given the current state
of docking programs and computational resources
available to CADD scientists, one can stipulate that modern docking
campaigns can rarely exceed 0.1 billion molecules and that the current
chemical space remains largely inaccessible to structure-based drug
discovery. One common approach to address this disparity is to filter
large chemical collections to manageable drug-, lead-, fragment-,
and hit-like subsets (among others) using precomputed physicochemical
parameters and drug-like criteria, such as molecular weight, volume,
octanol–water partition coefficient, polar surface area, number
or rotatable bonds, number of hydrogen bond donors and acceptors,
among many others.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> While this approach
can effectively reduce an ultralarge docking database to manageable
subsets, many potentially useful compounds and novel or unconventional
chemotypes (notably emerging from such large collections<sup><xref ref-type="bibr" rid="ref6">6</xref></sup>) could be lost. In order to take a full advantage
of available and emerging “make-on-demand” chemicals,
it is essential to maximize the number of database entries tangibly
evaluated against a target of interest. It is also important to note
that a conventional docking workflow is remarkably neglectful of negative
results. A typical docking campaign relies on completing a full docking
run and selecting an extremely narrow subset of favorably docked molecules
(virtual hits) for future evaluation. Thus, the vast majority of docking
data (both favorable and, especially unfavorable) is not being utilized
in any way or form, while it could represent a very relevant, well-formatted,
and content-rich input for machine learning algorithms.</p>
    <p>Previously,
the possibility of predicting docking scores through
shallow quantitative structure–activity relationship (QSAR)
models has been explored by us (using 3D “inductive”
descriptors<sup><xref ref-type="bibr" rid="ref12">12</xref></sup>) and others, using a support
vector machine or random forest along with conformal predictors.<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> None of these methods, however, offer enough speed boost to deal
with billions of molecules, and such studies were thus limited to
a few millions of compounds at most. Deep learning (DL), on the other
hand, is particularly suited for large data set processing,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> and the method is rapidly gaining interest in
drug discovery due to its superior performance compared to traditional
machine learning techniques.<sup><xref ref-type="bibr" rid="ref16">16</xref>−<xref ref-type="bibr" rid="ref18">18</xref></sup> Thus, we anticipate that the
use of DL could unlock a full potential and true synergy between docking
and QSAR methodologies and will take a full advantage of ultralarge
docking database data.</p>
  </sec>
  <sec id="sec2">
    <title>Results</title>
    <p>In the current study, we
have introduced the use of fast-computed
and target-independent QSAR descriptors (such as 2D molecular fingerprint),
the use of iterative and fast random sampling of the docking database,
and, principally, the use of DL to predict docking scores of yet unprocessed
database entries at each iteration step. As a result, <italic>DD</italic> achieves up to 100-fold reduction of an ultralarge docking database
and up to 6000-fold enrichment for the top-ranked hits, while avoiding
significant loss of favorable virtual hits, as it will be discussed
below.</p>
    <sec id="sec2.1">
      <title><italic>DD</italic> Pipeline</title>
      <p>In its essence, the <italic>DD</italic> pipeline (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>) relies on the following consecutive steps:<list list-type="simple"><list-item><label>(a)</label><p>For each entry of
an ultralarge docking
database (such as ZINC15), the standard set of ligand-based QSAR descriptors
(such as molecular fingerprints) is computed;</p></list-item><list-item><label>(b)</label><p>A reasonably sized training subset
is randomly sampled from the database and docked into the target of
interest using conventional docking protocol(s);</p></list-item><list-item><label>(c)</label><p>The generated docking scores of the
training compounds are then related to their 2D molecular descriptors
through a DL model; a docking score cutoff (typically negative) is
then used to divide training compounds in virtual hits (scoring below
the cutoff) and nonhits (scoring above the cutoff);</p></list-item><list-item><label>(d)</label><p>The resulting QSAR deep model (trained
on empirical docking scores) is then used to predict docking outcomes
of yet unprocessed entries of the database. A predefined number of
predicted virtual hits are then randomly sampled and used for the
training set augmentation;</p></list-item><list-item><label>(e)</label><p>Steps b–d are repeated iteratively
until a predefined number of iterations is reached, and/or processed
entries of an ultralarge docking database are converged.</p></list-item></list></p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Schematic of the <italic>DD</italic> pipeline. (Top) <italic>DD</italic> initialization: a small sample of molecules is randomly extracted
from an ultralarge docking database and docked to a target under consideration.
The generated docking scores are then used to train a QSAR deep model.
The created QSAR solution is then used to predict docking outcome
for the remainder of a database and to return predicted virtual hits
required to start iteration 2. (Bottom) <italic>DD</italic> screening:
from iteration 2 onward, the deep model gets gradually improved by
augmenting the training set with randomly sampled QSAR-predicted virtual
hits from the previous <italic>DD</italic> iteration (which also get
selected for actual docking). The cycle is repeated for a predefined
number of iterations, after which <italic>DD</italic> returns top
scoring molecules from a database. This final library can be postprocessed
to remove residual low scoring entities. Alternatively, steps 2–11
can be carried out until the convergence of an ultralarge docking
database.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_0001" id="gr1" position="float"/>
      </fig>
      <p>In <italic>DD</italic>, the virtual
hits recall (i.e., the percentage
of actual virtual hits that is retrieved from the database) is set
implicitly through a probability threshold which is selected to include
90% of the actual virtual hits in the validation set. Then, the same
threshold is applied to the independent test set, and the recall of
virtual hits is evaluated in order to assess model generalizability.
If recalls of the validation and test sets are consistent with each
other, the model is applied to all entries of the database (more details
can be found in the <xref rid="sec4" ref-type="other">Methods</xref>). Although the
recall values could be endorsed explicitly by using, for example,
conformal predictors,<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref19">19</xref></sup> we did not observe significant
differences in the resulting performance of <italic>DD</italic>.</p>
      <p>The scripts to run <italic>DD</italic> pipeline are publicly available
in GitHub, together with instructions on how to setup runs and a few
additional tools to facilitate automation on HPC clusters, at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/vibudh2209/D2">https://github.com/vibudh2209/D2</uri>.</p>
    </sec>
    <sec id="sec2.2">
      <title>Ultra Large Docking Database Sampling</title>
      <p>Selection of
a representative and balanced training set is a critical step of any
modeling workflow. In the context of sampling a chemical space, a
proper <italic>DD</italic> training set should effectively reflect
database’s chemical diversity. It could be expected that enlarging
the sampling size and preclustering the docking base would ultimately
improve or even converge the chemical space coverage. On the other
hand, it is currently not feasible to cluster billions of chemical
structures in any way or form, and it has also been shown that preclustering
large libraries prior to docking can significantly lower the rank
of active chemotypes, thus hindering the discovery of new inhibitors
or activators.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Moreover, biasing sampling
toward molecules that are highly ranked by <italic>DD</italic> as
potential virtual hits could exclude low ranked, yet true positive
molecules from being selected for model training; therefore we selected
random sampling for all <italic>DD</italic> iterations. Finally, the
size of <italic>DD</italic> training set (e.g., the amount of actual
docking) would have a pivotal impact on a computational runtime and
should be carefully controlled.</p>
      <p>To establish an optimal sampling
of ZINC15 base, we evaluated the relationship between the size of <italic>DD</italic> training set and the corresponding means and standard
deviations of the test set recall values, reflecting the consistency
of model’s performance and its generalizability. For that,
we evaluated 12 protein targets from four major drug-target families,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> including nuclear receptors represented by androgen
receptor (AR), estrogen receptor-alpha (ERα), and peroxisome
proliferator-activated receptor γ (PPARγ). Linases were
represented by calcium/calmodulin-dependent protein kinase kinase
2 (CAMKK2), cyclin-dependent kinase 6 (CDK6), and vascular endothelial
growth factor receptor 2 (VEGFR2). G protein-coupled receptors included
adenosine A2A receptor (ADORA2A), thromboxane A2 receptor (TBXA2R),
and angiotensin II receptor type 1 (AT1R). Ion channels were represented
by Nav1.7 sodium channel (Nav1.7), Gloeobacter ligand-gated ion channel
(GLIC), and gamma-aminobutyric acid receptor type A (GABAA) (more
details about the selected targets are reported in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00229/suppl_file/oc0c00229_si_001.pdf">Table S1</ext-link>). For all 12 studied targets, we investigated the
relationships between the sample size and resulting mean test set
recall values, which appear to converge to 0.90 when the training
set size ranges between 250 000 and 1 million molecules (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>a). We also observed
that the standard deviations converge to 0 at about 1 million sample
size (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>b). Thus,
we have set 1 million molecules as the standard sampling for <italic>DD</italic> workflow (more details can be found in the <xref rid="sec4" ref-type="other">Methods</xref>).</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Effect of training set sample size on model generalizability.
(a)
Mean values for test set recalls computed using different sample sizes.
Values approach 0.90 for all targets, when the training set size is
within 250 000 and 1 million molecules. (b) Variations of standard
deviations (STD) approach 0, for a sample size of 1 million molecules.
We ran one iteration for each target and repeated computations five
times at each sampling size.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_0002" id="gr2" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.3">
      <title>Size Reduction of ZINC15 by <italic>DD</italic> Virtual Screening</title>
      <p>The main goal of <italic>DD</italic> methodology is to reduce an
ultralarge docking database of billions of entries to a manageable
few-million-molecules subset which yet encompasses the vast majority
of virtual hits. This final molecular subset can then be normally
docked into the target using one or several docking programs or can
be postprocessed with other VS means. The <italic>DD</italic> method
relies on iterative improvement of the deep neural network (DNN) training
by expanding its training set with predicted hit molecules from each
previous iteration, while the deciding cutoff also gradually becomes
more stringent. We extensively evaluated the performance of this <italic>DD</italic> protocol by screening all 1.36 billion molecules from
ZINC15 against the 12 protein targets introduced above, using docking
program FRED.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> Notably, <italic>DD</italic> itself is not a docking engine, but a DL score predictor to be used
in conjunction with any docking program to rapidly eliminate <italic>a priori</italic> unfavorable, “undockable” molecular
entities, and therefore drastically increase the speed of actual docking.</p>
      <p>To demonstrate the power of <italic>DD</italic>, we tested the
pipeline with a fixed set of parameters, such as number of iterations,
recall values, and others, in order to provide an objective comparison
between the 12 investigated systems. It is foreseen that <italic>DD</italic> users may want to use different simulation parameters than ours,
which best suit their time and resource allocations: for example,
fewer iterations with more docking per iteration and less DL cycles
may be an optimal choice for computing clusters with many CPUs and
few GPUs, and vice versa.</p>
      <p>For each target, we ran a total of
11 <italic>DD</italic> iterations—one
initial training step (requiring docking of 3 million entries to build
training, validation and test sets of 1 million each) and 10 consecutive
iterative docking steps, each involving docking of 1 million molecules.
Thus, for each target we practically docked only 13 million molecular
structures representing less than 1% of the 1.36 billion entries of
ZINC15. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a illustrates
the docking score cutoffs used to discern hits and nonhits at each
iteration. These values decreased in accordance with the criterion
used for defining virtual hits, that becomes more stringent at each
iteration (see <xref rid="sec4" ref-type="other">Methods</xref> for details). The majority
of nonhits were removed during the first iteration for all targets,
while fewer molecules were discarded in successive steps, as expected
due to larger portions of unfavorable compounds being present at the
beginning of the runs. We observed that the decrease rate and the
number of hits identified were target-dependent (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>b). Another notable observation
from the analysis of the <italic>DD</italic> progression is that training
sets effectively improve after each iteration, since docking scores
of molecules added to training become more negative (favorable) after
each round of modeling (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>c). This observation marks progressively more confident performance
of <italic>DD</italic> in recognizing and discarding low scoring molecules,
and consequently favorably augmenting of the training set. Consequently,
we anticipated that <italic>DD</italic> is likely to improve the enrichment
for virtual hits after each iteration, as visible in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>d, featuring enrichment values
for the top 100 molecules ranked by the DNN models in the test sets.
As the data indicate, these values increased after each iteration
for all targets, also suggesting that model’s performance improves
every time the training set is augmented with molecules from each
previous <italic>DD</italic> iteration. Of note, the enrichment values
become strongly increased at last iteration, where the models retrieved
a very small portion (0.01%) of the top scoring molecules of the database.
Further indications of iterative improvement of DNN models are provided
by the area under the curve receiver operating characteristics (AUC
ROC) values and full predicted database enrichment (FPDE) values,
presented in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00229/suppl_file/oc0c00229_si_002.xlsx">Table S3</ext-link> for all iterations
of the 12 studied targets, as well as the precision of the models
to identify high scoring molecules, which improved at each iteration
as well, as expected (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00229/suppl_file/oc0c00229_si_001.pdf">Figure S2</ext-link>).</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><italic>DD</italic> performance statistics for 12 drug targets.
(a) Variation of score cutoff values used for selecting virtual hits
at each iteration. (b) Variation of numbers of molecules predicted
as virtual hits after each iteration. (c) Iterative improvement of
docking score mean values for randomly selected molecules used for
training set augmentation. (d) Enrichment values calculated for 100
top ranked predicted virtual hits in test set after each iteration.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_0003" id="gr3" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.4">
      <title>Analysis of <italic>DD</italic> Performance</title>
      <p>As indicated
earlier, the main objective of the <italic>DD</italic> methodology
is to reduce an ultralarge docking database to a highly enriched library
of molecules that can be processed using conventional docking programs
and computational resources. While studying 12 selected targets, we
observed that the sizes of final, remaining subsets ranged between
1% and 12% of the original ultralarge docking database (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a). It is foreseen that these
remaining enriched and DNN-ranked libraries can then be postprocessed
to remove residual low scoring molecules. Alternatively, <italic>DD</italic> can be carried out until the convergence of an ultralarge docking
database.</p>
      <fig id="fig4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Final data set sizes and enrichment values resulting from <italic>DD</italic> runs. (a) Total number of molecules predicted as virtual
hits remaining after the 11th <italic>DD</italic> iteration. Values
are also reported in terms of percentage of ZINC15 entries that were
retained (right vertical axis). (b) FPDE values resulting from the
last iterations of <italic>DD</italic> experiments. (c) Enrichment
values for top 10, top 100, and top 1000 selected virtual hits (in
the test sets).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_0004" id="gr4" position="float"/>
      </fig>
      <p><italic>DD</italic> demonstrated
its best performance for PPARγ
protein, where the database was reduced to 1% of its size. Thus, considering
docking required to train the model as well as to postprocess the
final subset, <italic>DD</italic> screening of ZINC15 against this
target requires docking of 50 times fewer molecules than conventional
VS. On the other hand, <italic>DD</italic> was least effective on
the GABAA target, where 12% of ZINC15 molecules were left after the
last iteration due to low precision of the model. These results clearly
suggest that, like any other computational tool, <italic>DD</italic> shows performances that are target-dependent. Encouragingly, the
recall values were consistently transferred to the test sets in all
cases (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00229/suppl_file/oc0c00229_si_002.xlsx">Table S3</ext-link>). We also compared
the number of molecules expected to be returned by <italic>DD</italic> at each iteration based on the test sets with the number that was
actually returned when <italic>DD</italic> models were applied to
ZINC15, observing no significant differences (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00229/suppl_file/oc0c00229_si_001.pdf">Figure S3</ext-link>). Taken together, these results suggest that all
underlying DL models were generalizable in a consistent way. To further
assess the overall <italic>DD</italic> performance, we evaluated final
FPDE values, which ranged from 8 to 89, indicating that <italic>DD</italic> enriched final subsets with high scoring molecules in a target-dependent
way. As expected, FPDE values matched the trends observed for the
number of <italic>DD</italic> predicted virtual hits (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>b).</p>
      <p>We also evaluated
enrichment values for the top 10, 100, and 1000
predicted virtual hits identified in the test sets after the final
iteration, observing values ranging from 240 to 6000 as demonstrated
on <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>c. Such
enrichments decreased consistently in all cases when evaluating larger
portions of top ranked structures, thus suggesting that true hits
are highly concentrated at the top of the <italic>DD</italic> rank,
and molecules at the bottom of the rank are mostly false positives.
It is important to note that we have set stringent 0.90 recall values
for our <italic>DD</italic> runs to preserve the vast majority of
virtual hits in the final subset. However, one can lower such recall
cutoff to sacrifice the retention of virtual hits in a <italic>DD</italic> workflow, but to significantly reduce the number of unprocessed
molecules retained at the end, and to shorten the runtime.</p>
      <p>To
investigate the effect of decreasing the recall of virtual hits,
we ran <italic>DD</italic> for two systems, namely, PPARγ and
GABAA (the best and worst targets in terms of number of molecules
remained unprocessed after 11 <italic>DD</italic> iterations as described
above), using recall values of 0.75 and 0.60. Encouragingly, the number
of remaining entries significantly decreased in both cases compared
to <italic>DD</italic> runs with 0.90 recall (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>a). For the PPARγ system, the size
of ZINC15 was scaled down 800 times at 0.75 recall, and 2300 times
at 0.60. Similarly, we observed a 66- and 654-fold size reduction
using recalls of 0.75 and 0.60 respectively, for the GABAA target.
Importantly, the enrichment of the molecular subsets increased noticeably
when lower recalls were used, reaching up to 1450 for FPDE values
and again clearly indicating that density of virtual hits rapidly
decreases as we move away from the top of the DNN rank (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>b). Thus, the recall value
can be chosen according to the needed speed boost or computational
resources available to the user in order to further reduce the amount
of docking and/or postprocessing required at the end of <italic>DD</italic> runs.</p>
      <fig id="fig5" position="float">
        <label>Figure 5</label>
        <caption>
          <p><italic>DD</italic> size reduction power depends on recall values.
(a) Final number of molecule (in logarithmic scale) predicted as virtual
hits by DD and (b) FPDE values obtained for PPARγ and GABAA
systems by varying the virtual hit recall values.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_0005" id="gr5" position="float"/>
      </fig>
      <p>Overall, the above analysis indicates that the <italic>DD</italic> procedure can effectively discard most of unqualified molecules
in a ultra large docking database, without losing more than a predefined
percentage of virtual hits. In our opinion, this makes <italic>DD</italic> methodology an efficient mean for conducting large-scale VS campaigns
involving billions of small molecule structures, and a valid alternative
to brute force approaches demanding large amounts of computational
resources.</p>
    </sec>
    <sec id="sec2.5">
      <title><italic>DD</italic> Virtual Screening and
Active Ligands</title>
      <p>We also investigated how <italic>DD</italic> method deals with active
ligands that are present in ultralarge docking databases. For five
of the investigated systems, namely, AR, ERα, PPARγ, VEGFR2,
and ADORA2A, the Database of Useful Decoys: Enhanced<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> (DUD-E) provided sets of confirmed active ligands (details
about the data sets are reported in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00229/suppl_file/oc0c00229_si_001.pdf">Table S2</ext-link>) that we docked to their respective targets together with 1 million
of random compounds from ZINC15 (considered as inactive molecules).
Docking performances of FRED were variable across targets, with AUC
ROC values ranging from 0.52 to 0.91 (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>a). In parallel, we evaluated how <italic>DD</italic> ranks of compounds (evaluated at 0.90 recall) correlated
with their docking scores, in particular, with their distance from
the score cutoff used to define virtual hits and nonhits in the last
iteration, using random samples of 1 million ZINC15 molecules docked
to each target (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>b). <italic>DD</italic> appears to clearly bias final sets toward
high docking scores, and since active ligands score better than inactives
based on AUC values, we expected active ligands to be discarded at
lower rates than inactive molecules. Thus, we plotted the rank of
active ligands against their score distance from the virtual hit cutoff
(<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>c). As expected, <italic>DD</italic> worked particularly well for systems with many high scoring
actives and good AUC values, such as AR and ERα, for which all
active, top scoring ligands were retained. Interestingly, <italic>DD</italic> retained also a significantly large amount of active
ligands with nonhits scores for all targets, at about 10-fold higher
rates than remaining ZINC15 nonhits.</p>
      <fig id="fig6" position="float">
        <label>Figure 6</label>
        <caption>
          <p>(a) ROC curves for FRED docking of active
ligands to five targets.
Actives were mixed with 1 million of randomly sampled ZINC15 molecules.
AUC value for each target is reported in brackets. (b) <italic>DD</italic> rank (logarithmic scale) versus distance of scores from cutoff values
of random samples of 1 million ZINC15 compounds docked to the five
targets. (c) <italic>DD</italic> rank (logarithmic scale) versus distance
from score cutoff for active ligands. Kept (recalled) ligands are
represented with yellow dots, discarded ligands are represented with
blue dots. (d) Enrichment factor (EF, logarithmic scale) of active
ligands when top 100 000, 1 000 000, 10 000 000,
and all <italic>DD</italic> hits are considered.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_0006" id="gr6" position="float"/>
      </fig>
      <p>Then, we calculated the enrichment factors (EFs) for active compounds
on top 100 000, 1 000 000, and 10 000 000
ranked molecules, for the fivr systems. Not surprisingly, the highest
values were observed for AR and ERα, for which EFs for the top
100 000 molecules were encouragingly high, 660 for AR and 477
for ERα, and consistently decreased by evaluating larger portion
of top scoring molecules (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>d). For the other three systems, a clear trend for
enrichments was not observed when different sizes were considered.
Nevertheless, all the considered subsets of molecules were enriched
with active ligands, showing EFs of at least six. Thus, selecting
a subset of top ranked DD molecules seems to be a valid alternative
to lowering the recall value in order to limit the amount of final
docking, when limited computational resources are available. Furthermore,
EFs calculated over all <italic>DD</italic> hits ranged between 11
and 14 for all systems. Thus, <italic>DD</italic> not only enables
extraction of controlled portions of virtual hits from an ultralarge
docking database, but also enriches final subsets with active hit
molecules. Remarkably, this unexpected <italic>DD</italic> feature
of retaining actives regardless of their scores resulted in enrichment
also for targets showing near-to-random docking performance, such
as the ADORA2A system.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Discussion</title>
    <p>With the increasing automation
of synthetic procedures, the focus
of modern drug discovery campaigns will be shifting toward screening
of increasingly larger molecular libraries consisting of billions
of chemical structures. To reinforce such opportunity, docking protocols
demonstrate improved performance on larger make-on-demand databases,
effectively yielding novel, diverse, and nontraditional chemotypes
for drug discovery endeavors.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> It could
be noted, however, that most of time and resources invested in modern
docking campaigns are spent on processing unfavorable molecular structures,
while the emerging “negative” data are also not being
utilized in any way or form.</p>
    <p>Hence, to keep the pace with an
ever-expanding chemical Big Data
space and to fully utilize results generated by docking programs “on
a fly”, we have developed the Deep Docking protocol <italic>DD</italic>, a DNN-based method for processing large chemical libraries
with conventional computational and software resources. The method
relies on iterative docking of a small portion of a parental ultralarge
docking database (such as ZINC15) using a docking program of choice
and utilizes generated scores (both favorable and unfavorable) to
train ligand-based QSAR models. These models then enable approximation
of the docking outcome for unprocessed database entries. Importantly,
DL allows the use of simple 2D protein-independent descriptors such
as Morgan fingerprints to capture the docking scores. We have demonstrated
that such approach can yield a manageably small subset of a database,
highly enriched with favorably “dockable” molecular
structures.</p>
    <p>We proved the power of <italic>DD</italic> by screening
all 1.36
billion entries of ZINC15 against 12 prominent drug targets, where
the original ultralarge docking database was significantly reduced
while retrieving a controlled, high portion of favorably docked molecules.
At the same time, most of low scoring molecules were removed without
investing time and resources in them, and the generated ZINC subsets
were highly enriched in potential virtual hits. Notably, screening
an ultralarge docking database using <italic>DD</italic> requires
docking up to 50 times fewer molecules compared to conventional docking,
while losing only about 10% of virtual hits. We also showed that <italic>DD</italic> can further shrink an ultralarge docking database to
a few hundreds of thousands of molecules while still retrieving a
significant part (60%) of top scoring hits. Moreover, <italic>DD</italic> appears to enrich final subsets with active ligands, even when only
small portions of top ranked molecules are considered. This unexpected
result suggests that true binders carry on certain chemical features
that are complementary to the binding pocket and that the model is
able to capture such features through the QSAR descriptors.</p>
  </sec>
  <sec id="sec4">
    <title>Conclusion</title>
    <p>In the current work, we introduced the use of deep learning in
structure-based drug discovery in a novel way. The developed Deep
Docking approach utilizes QSAR models trained on actual docking scores
of a small subset of a molecular database to predict docking scores
for the rest. Such approach, being used in an iterative manner (with
predefined recall parameters) allows significant savings of docking
runtime, without notable loss of potentially “dockable”
entities or active ligands. The use of Deep Docking circumvents computational
limits of large-scale docking campaigns and makes billion-entries
molecular databases accessible even with limited computational resources.</p>
    <p>Collectively, our results strongly advocate the use of deep learning
for exploration of continuously expanding chemical space in search
for new therapeutics.</p>
  </sec>
  <sec id="sec5">
    <title>Methods</title>
    <sec id="sec5.1">
      <title>QSAR Descriptors</title>
      <p>SMILES of 1.36 billion molecular structures
were downloaded from ZINC15.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Morgan fingerprints
with a size of 1024 bits and a radius of 2 were generated using the
RDKit package.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p>
    </sec>
    <sec id="sec5.2">
      <title>Protein Targets</title>
      <p>The X-ray structures of AR,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> ERα,<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> PPARγ,<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> CAMKK2,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> CDK6,<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> VEGFR2,<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> ADORA2A,<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> TBXA2R,<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> AT1R,<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Nav1.7,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> GLIC,<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> and GABAA<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> containing
cocrystallized ligands were extracted from the Protein Data Bank (PDB).<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Details about the selected target structures
are summarized in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00229/suppl_file/oc0c00229_si_001.pdf">Table S1</ext-link>.</p>
    </sec>
    <sec id="sec5.3">
      <title>Molecular Docking</title>
      <p>PDB structures were optimized using
the Protein Preparation Wizard module from the Schrödinger
suite,<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> and docking grids were prepared
using the MakeReceptor utility from OpenEye.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> SMILES were processed using QUACPAC<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> in
order to generate dominant tautomer and ionization states at pH 7.4.
The OMEGA’s pose module<sup><xref ref-type="bibr" rid="ref39">39</xref>,<xref ref-type="bibr" rid="ref40">40</xref></sup> was used to generate
multiple 3D optimal conformers for FRED docking. Docking simulations
were carried out using FRED program and Chemgauss4 scoring function
from OpenEye.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup></p>
    </sec>
    <sec id="sec5.4">
      <title>Database Sampling</title>
      <p>The optimal number of molecules required
for the training set was determined by running one <italic>DD</italic> iteration for each target, using different sizes for training, validation,
and test set (10 000, 20 000, 40 000, 80 000,
160 000, 320 000, 640 000, and 1 million molecules).
For each sample size, computations were repeated five independent
times. The optimal sampling size was then chosen by evaluating means
and standard deviations of recall values in the test sets for all
targets.</p>
    </sec>
    <sec id="sec5.5">
      <title><italic>DD</italic> Workflow</title>
      <p>Initial training, validation,
and test sets used for the DL model consisted of 1 million molecules
each that were randomly sampled from ZINC15 during the first <italic>DD</italic> iteration. Each set was docked to the target of interest
and then divided into virtual hits and nonhits based on the generated
docking scores. The score cutoff used to determine the class of molecules
was determined in order to split the validation in 1% top scoring
molecules (virtual hits) and 99% nonhits. Molecules of each set with
docking scores equal or more favorable than the cutoff value were
assigned to the virtual hit class, while remaining molecules were
assigned to the nonhit class. The DNN model was trained using classes
and molecular descriptors of the processed entries and then used to
predict virtual hits and unqualified molecules from the whole ZINC15
based on molecular descriptors. From the second iteration onward,
the training set was expanded with 1 million molecules randomly sampled
from hits predicted in the previous iteration, while validation and
test sets remained unchanged for all the length of the <italic>DD</italic> run. The score cutoff was gradually decreased (corresponding to
higher predicted target affinity) after each iteration to keep selecting
better compounds. This reduction was done by linearly lowering the
percentage of top scoring molecules in the validation set assigned
to the virtual hit class from 1% in the first iteration to 0.01% in
the last one. A linear variation of the score cutoff was chosen in
order to avoid large variations in initial iterations, which could
restrict the model to comprehensively explore chemical classes. Thus,
the cutoff value in iteration 2 corresponded to the highest (worst)
docking score of the top 0.9% ranked compounds, in iteration 3 it
corresponded to the highest docking score of top 0.8% compounds, and
so on.</p>
    </sec>
    <sec id="sec5.6">
      <title>Evaluation Metrics</title>
      <p>All evaluation metrics were calculated
on the test sets. Precision was calculated as<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_m001" position="anchor"/><label>1</label></disp-formula>where
TP (true positives) were virtual hits
correctly predicted by the DNN, and FP (false positives) were actual
nonhits that were incorrectly classified as virtual hits by the DNN.</p>
      <p>Recall was calculated as<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_m002" position="anchor"/><label>2</label></disp-formula>where FN (false negatives) were virtual hits
incorrectly discarded by the DNN.</p>
      <p>Enrichment values were calculated
as<disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_m003" position="anchor"/><label>3</label></disp-formula>with
TP|<sub>top N</sub> as the number
of TP found within the top <italic>N</italic> ranked molecules by
the DNN, and TP|<sub>random <italic>N</italic></sub> as the number
of TP found within <italic>N</italic> randomly sampled molecules. <italic>N</italic> was set to values equal to 10, 100, and 1000.</p>
      <p>FPDE
was calculated as the ratio between precision (<xref rid="eq1" ref-type="disp-formula">eq <xref rid="eq1" ref-type="disp-formula">1</xref></xref>) and random precision:<disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_m004" position="anchor"/><label>4</label></disp-formula></p>
    </sec>
    <sec id="sec5.7">
      <title>Deep Learning</title>
      <p>The Keras Python library<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> was used for
building and training feed-forward DNN models.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> Model hyperparameters were set as the number
of hidden layers and neurons, dropout frequency, as well as oversampling
of the minority class and class weights, in order to deal with highly
imbalanced data sets (1–0.01% of virtual hits). A lower threshold
value was established for the DNN probabilities (indicating the likelihood
of molecules of being virtual hits) and used as criterion to assign
molecules to the virtual hit class upon prediction. The threshold
was chosen each time in order to retrieve 90% of the actual virtual
hits (i.e., top scoring molecules) of the validation set. Model selection
was performed by running a basic grid search to identify the set of
hyperparameters providing the highest FPDE value in the test set.
The best model was then applied to all ZINC15 entries in order to
predict virtual hits and nonhits.</p>
    </sec>
    <sec id="sec5.8">
      <title>Active Ligands</title>
      <p>Active compounds were obtained from
the DUD-E repository for available targets.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> If not already present in ZINC15, SMILES and relative Morgan fingerprints
of compounds were calculated and added to it. The molecules were prepared
and docked to the respective targets as previously described. Enrichment
factors after top <italic>N</italic> molecules,<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> ranked by <italic>DD</italic> probability of virtual hit-likeness,
were calculated as<disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_m005" position="anchor"/><label>5</label></disp-formula>with
actives|<sub><italic>N</italic></sub> being the number of active ligands
found in top <italic>N</italic> molecules, actives|<sub>database</sub> the total number of active
ligands, and mol|<sub>database</sub> the database size.</p>
    </sec>
    <sec id="sec5.9">
      <title>Hardware</title>
      <p>We used a 6 Intel(R) Xeon(R) Silver 4116 CPU
@ 2.10 GHz (a total of 60 cores) for docking and 4 Nvidia Tesla V100
GPUs with 32 GB memory for DNN model training and inference.</p>
    </sec>
  </sec>
</body>
<back>
  <notes id="notes1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acscentsci.0c00229?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acscentsci.0c00229</ext-link>.<list id="silist" list-type="simple"><list-item><p>Docking results of cocrystallized
ligands, additional
performance analysis, details about protein targets, details of DUD-E
ligands, supplementary references (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00229/suppl_file/oc0c00229_si_001.pdf">PDF</ext-link>)</p></list-item><list-item><p><italic>DD</italic> code is publicly available
in GitHub
at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/vibudh2209/D2">https://github.com/vibudh2209/D2</uri>. Docking data sets used for building models reported in the manuscript
are freely available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://drive.google.com/drive/folders/1UNGfkGiL_8heQWwxaaQPfIoU4AAqoUoA">https://drive.google.com/drive/folders/1UNGfkGiL_8heQWwxaaQPfIoU4AAqoUoA</uri>.</p></list-item><list-item><p>AUC ROC and FPDE values for all iterations
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00229/suppl_file/oc0c00229_si_002.xlsx">XLSX</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_si_001.pdf">
        <caption>
          <p>oc0c00229_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="oc0c00229_si_002.xlsx">
        <caption>
          <p>oc0c00229_si_002.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="" id="notes2">
    <title>Author Contributions</title>
    <p>A.C., F.G.,
and V.A. designed research. F.G., V.A., and M.H. performed research.
F.G., V.A., M.H., A.-T.T, F.B., and U.N. analyzed data. F.G., M.H.,
and A.C. drafted the manuscript, with all authors contributing. A.C.
and M.E.G. supervised the research.</p>
  </notes>
  <notes notes-type="" id="notes3">
    <title>Author Contributions</title>
    <p><sup>#</sup> F.G. and V.A.
contributed equally.</p>
  </notes>
  <notes notes-type="COI-statement" id="notes4">
    <p>The authors
declare no competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This work has been supported
by the Canadian Cancer
Society Research Institute (CCSRI) Impact Grant 2019 No. 706145. F.G.
would like to thank the Ermenegildo Zegna Founder’s scholarship
program for financial support.</p>
  </ack>
  <glossary id="dl1">
    <def-list>
      <title>Abbreviations</title>
      <def-item>
        <term>CADD</term>
        <def>
          <p>computer-aided drug discovery</p>
        </def>
      </def-item>
      <def-item>
        <term>VS</term>
        <def>
          <p>virtual screening</p>
        </def>
      </def-item>
      <def-item>
        <term>QSAR</term>
        <def>
          <p>quantitative structure–activity
relationship</p>
        </def>
      </def-item>
      <def-item>
        <term>DL</term>
        <def>
          <p>deep learning</p>
        </def>
      </def-item>
      <def-item>
        <term>DD</term>
        <def>
          <p>Deep Docking</p>
        </def>
      </def-item>
      <def-item>
        <term>AR</term>
        <def>
          <p>androgen receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>ERα</term>
        <def>
          <p>estrogen receptor-alpha</p>
        </def>
      </def-item>
      <def-item>
        <term>PPARγ</term>
        <def>
          <p>peroxisome proliferator-activated receptor
γ</p>
        </def>
      </def-item>
      <def-item>
        <term>CAMKK2</term>
        <def>
          <p>calcium/calmodulin-dependent
protein kinase kinase 2</p>
        </def>
      </def-item>
      <def-item>
        <term>CDK6</term>
        <def>
          <p>cyclin-dependent kinase 6</p>
        </def>
      </def-item>
      <def-item>
        <term>VEGFR2</term>
        <def>
          <p>vascular endothelial growth factor receptor
2</p>
        </def>
      </def-item>
      <def-item>
        <term>ADORA2A</term>
        <def>
          <p>adenosine
A2A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>TBXA2R</term>
        <def>
          <p>thromboxane A2 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>AT1R</term>
        <def>
          <p>angiotensin II receptor type 1</p>
        </def>
      </def-item>
      <def-item>
        <term>Nav1.7</term>
        <def>
          <p>Nav1.7 sodium channel</p>
        </def>
      </def-item>
      <def-item>
        <term>GLIC</term>
        <def>
          <p>Gloeobacter ligand-gated ion channel</p>
        </def>
      </def-item>
      <def-item>
        <term>GABAA</term>
        <def>
          <p>gamma-aminobutyric
acid receptor type A</p>
        </def>
      </def-item>
      <def-item>
        <term>DNN</term>
        <def>
          <p>deep neural network</p>
        </def>
      </def-item>
      <def-item>
        <term>AUC ROC</term>
        <def>
          <p>area under the curve receiver operating characteristics</p>
        </def>
      </def-item>
      <def-item>
        <term>FPDE</term>
        <def>
          <p>full predicted
database enrichment</p>
        </def>
      </def-item>
      <def-item>
        <term>PDB</term>
        <def>
          <p>Protein Data Bank</p>
        </def>
      </def-item>
      <def-item>
        <term>TP</term>
        <def>
          <p>true positives</p>
        </def>
      </def-item>
      <def-item>
        <term>FP</term>
        <def>
          <p>false positives</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>DiMasi</surname><given-names>J. A.</given-names></name>; <name><surname>Grabowski</surname><given-names>H. G.</given-names></name>; <name><surname>Hansen</surname><given-names>R. W.</given-names></name><article-title>Innovation in the pharmaceutical
industry: new estimates of R&amp;D costs</article-title>. <source>Journal
of Health Economics</source><year>2016</year>, <volume>47</volume>, <fpage>20</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhealeco.2016.01.012</pub-id>.<pub-id pub-id-type="pmid">26928437</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Hughes</surname><given-names>J. P.</given-names></name>; <name><surname>Rees</surname><given-names>S.</given-names></name>; <name><surname>Kalindjian</surname><given-names>S. B.</given-names></name>; <name><surname>Philpott</surname><given-names>K. L.</given-names></name><article-title>Principles of early
drug discovery</article-title>. <source>Br. J. Pharmacol.</source><year>2011</year>, <volume>162</volume> (<issue>6</issue>), <fpage>1239</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01127.x</pub-id>.<pub-id pub-id-type="pmid">21091654</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Ban</surname><given-names>F.</given-names></name>; <name><surname>Dalal</surname><given-names>K.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>LeBlanc</surname><given-names>E.</given-names></name>; <name><surname>Rennie</surname><given-names>P. S.</given-names></name>; <name><surname>Cherkasov</surname><given-names>A.</given-names></name><article-title>Best Practices
of Computer-Aided Drug Discovery: Lessons
Learned from the Development of a Preclinical Candidate for Prostate
Cancer with a New Mechanism of Action</article-title>. <source>J. Chem.
Inf. Model.</source><year>2017</year>, <volume>57</volume> (<issue>5</issue>), <fpage>1018</fpage>–<lpage>1028</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.7b00137</pub-id>.<pub-id pub-id-type="pmid">28441481</pub-id></mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>ZINC--a free database of commercially
available compounds
for virtual screening</article-title>. <source>J. Chem. Inf. Model.</source><year>2005</year>, <volume>45</volume> (<issue>1</issue>), <fpage>177</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1021/ci049714+</pub-id>.<pub-id pub-id-type="pmid">15667143</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Sterling</surname><given-names>T.</given-names></name>; <name><surname>Irwin</surname><given-names>J. J.</given-names></name><article-title>ZINC 15--Ligand
Discovery for Everyone</article-title>. <source>J. Chem. Inf. Model.</source><year>2015</year>, <volume>55</volume> (<issue>11</issue>), <fpage>2324</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00559</pub-id>.<pub-id pub-id-type="pmid">26479676</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><person-group person-group-type="allauthors"><name><surname>Stumpfe</surname><given-names>D.</given-names></name>; <name><surname>Bajorath</surname><given-names>J.</given-names></name></person-group><article-title>Current Trends,
Overlooked Issues, and Unmet Challenges in Virtual Screening</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>,<pub-id pub-id-type="doi">10.1021/acs.jcim.9b01101</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Lyu</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Balius</surname><given-names>T. E.</given-names></name>; <name><surname>Singh</surname><given-names>I.</given-names></name>; <name><surname>Levit</surname><given-names>A.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>O’Meara</surname><given-names>M. J.</given-names></name>; <name><surname>Che</surname><given-names>T.</given-names></name>; <name><surname>Algaa</surname><given-names>E.</given-names></name>; <name><surname>Tolmachova</surname><given-names>K.</given-names></name>; <name><surname>Tolmachev</surname><given-names>A. A.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Irwin</surname><given-names>J. J.</given-names></name><article-title>Ultra-large library docking for discovering new chemotypes</article-title>. <source>Nature</source><year>2019</year>, <volume>566</volume> (<issue>7743</issue>), <fpage>224</fpage><pub-id pub-id-type="doi">10.1038/s41586-019-0917-9</pub-id>.<pub-id pub-id-type="pmid">30728502</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="computer-program" id="cit8"><source>QUACPAC 2.0.1.2</source>; <publisher-name>OpenEye
Scientific
Software</publisher-name>, <publisher-loc>Santa Fe, NM, USA</publisher-loc>, <year>2019</year>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Stein</surname><given-names>R. M.</given-names></name>; <name><surname>Kang</surname><given-names>H. J.</given-names></name>; <name><surname>McCorvy</surname><given-names>J. D.</given-names></name>; <name><surname>Glatfelter</surname><given-names>G. C.</given-names></name>; <name><surname>Jones</surname><given-names>A. J.</given-names></name>; <name><surname>Che</surname><given-names>T.</given-names></name>; <name><surname>Slocum</surname><given-names>S.</given-names></name>; <name><surname>Huang</surname><given-names>X. P.</given-names></name>; <name><surname>Savych</surname><given-names>O.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Stauch</surname><given-names>B.</given-names></name>; <name><surname>Johansson</surname><given-names>L. C.</given-names></name>; <name><surname>Cherezov</surname><given-names>V.</given-names></name>; <name><surname>Kenakin</surname><given-names>T.</given-names></name>; <name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Dubocovich</surname><given-names>M. L.</given-names></name><article-title>Virtual
discovery of melatonin receptor
ligands to modulate circadian rhythms</article-title>. <source>Nature</source><year>2020</year>, <volume>579</volume> (<issue>7800</issue>), <fpage>609</fpage>–<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2027-0</pub-id>.<pub-id pub-id-type="pmid">32040955</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Gorgulla</surname><given-names>C.</given-names></name>; <name><surname>Boeszoermenyi</surname><given-names>A.</given-names></name>; <name><surname>Wang</surname><given-names>Z. F.</given-names></name>; <name><surname>Fischer</surname><given-names>P. D.</given-names></name>; <name><surname>Coote</surname><given-names>P.</given-names></name>; <name><surname>Padmanabha Das</surname><given-names>K. M.</given-names></name>; <name><surname>Malets</surname><given-names>Y. S.</given-names></name>; <name><surname>Radchenko</surname><given-names>D. S.</given-names></name>; <name><surname>Moroz</surname><given-names>Y. S.</given-names></name>; <name><surname>Scott</surname><given-names>D. A.</given-names></name>; <name><surname>Fackeldey</surname><given-names>K.</given-names></name>; <name><surname>Hoffmann</surname><given-names>M.</given-names></name>; <name><surname>Iavniuk</surname><given-names>I.</given-names></name>; <name><surname>Wagner</surname><given-names>G.</given-names></name>; <name><surname>Arthanari</surname><given-names>H.</given-names></name><article-title>An open-source
drug discovery platform enables ultra-large virtual screens</article-title>. <source>Nature</source><year>2020</year>, <volume>580</volume>, <fpage>663</fpage><pub-id pub-id-type="doi">10.1038/s41586-020-2117-z</pub-id>.<pub-id pub-id-type="pmid">32152607</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Lipinski</surname><given-names>C. A.</given-names></name><article-title>Lead-and
drug-like compounds: the rule-of-five revolution</article-title>. <source>Drug Discovery Today: Technol.</source><year>2004</year>, <volume>1</volume> (<issue>4</issue>), <fpage>337</fpage>–<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.007</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Cherkasov</surname><given-names>A. R.</given-names></name>; <name><surname>Galkin</surname><given-names>V. I.</given-names></name>; <name><surname>Cherkasov</surname><given-names>R. A.</given-names></name><article-title>A new approach
to the theoretical
estimation of inductive constants</article-title>. <source>J. Phys.
Org. Chem.</source><year>1998</year>, <volume>11</volume> (<issue>7</issue>), <fpage>437</fpage>–<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1099-1395(199807)11:7&lt;437::AID-POC4&gt;3.0.CO;2-C</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Ahmed</surname><given-names>L.</given-names></name>; <name><surname>Georgiev</surname><given-names>V.</given-names></name>; <name><surname>Capuccini</surname><given-names>M.</given-names></name>; <name><surname>Toor</surname><given-names>S.</given-names></name>; <name><surname>Schaal</surname><given-names>W.</given-names></name>; <name><surname>Laure</surname><given-names>E.</given-names></name>; <name><surname>Spjuth</surname><given-names>O.</given-names></name><article-title>Efficient
iterative virtual screening
with Apache Spark and conformal prediction</article-title>. <source>J. Cheminf.</source><year>2018</year>, <volume>10</volume> (<issue>1</issue>), <fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0265-z</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Svensson</surname><given-names>F.</given-names></name>; <name><surname>Norinder</surname><given-names>U.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name><article-title>Improving screening efficiency through
iterative screening using docking and conformal prediction</article-title>. <source>J. Chem. Inf. Model.</source><year>2017</year>, <volume>57</volume> (<issue>3</issue>), <fpage>439</fpage>–<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00532</pub-id>.<pub-id pub-id-type="pmid">28195474</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Olivecrona</surname><given-names>M.</given-names></name>; <name><surname>Blaschke</surname><given-names>T.</given-names></name><article-title>The rise of deep learning in drug
discovery</article-title>. <source>Drug Discovery Today</source><year>2018</year>, <volume>23</volume> (<issue>6</issue>), <fpage>1241</fpage>–<lpage>1250</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2018.01.039</pub-id>.<pub-id pub-id-type="pmid">29366762</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Mayr</surname><given-names>A.</given-names></name>; <name><surname>Klambauer</surname><given-names>G.</given-names></name>; <name><surname>Unterthiner</surname><given-names>T.</given-names></name>; <name><surname>Hochreiter</surname><given-names>S.</given-names></name><article-title>DeepTox: Toxicity
Prediction using Deep Learning</article-title>. <source>Front. Environ.
Sci.</source><year>2016</year>, <volume>3</volume>, <fpage>80</fpage><pub-id pub-id-type="doi">10.3389/fenvs.2015.00080</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Fernandez</surname><given-names>M.</given-names></name>; <name><surname>Ban</surname><given-names>F.</given-names></name>; <name><surname>Woo</surname><given-names>G.</given-names></name>; <name><surname>Hsing</surname><given-names>M.</given-names></name>; <name><surname>Yamazaki</surname><given-names>T.</given-names></name>; <name><surname>LeBlanc</surname><given-names>E.</given-names></name>; <name><surname>Rennie</surname><given-names>P. S.</given-names></name>; <name><surname>Welch</surname><given-names>W. J.</given-names></name>; <name><surname>Cherkasov</surname><given-names>A.</given-names></name><article-title>Toxic Colors:
The Use of Deep Learning for Predicting Toxicity of Compounds Merely
from Their Graphic Images</article-title>. <source>J. Chem. Inf. Model.</source><year>2018</year>, <volume>58</volume> (<issue>8</issue>), <fpage>1533</fpage>–<lpage>1543</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00338</pub-id>.<pub-id pub-id-type="pmid">30063345</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Playe</surname><given-names>B.</given-names></name>; <name><surname>Stoven</surname><given-names>V.</given-names></name><article-title>Evaluation of deep and shallow learning methods in
chemogenomics for the prediction of drugs specificity</article-title>. <source>J. Cheminf.</source><year>2020</year>, <volume>12</volume> (<issue>1</issue>), <fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s13321-020-0413-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Shafer</surname><given-names>G.</given-names></name>; <name><surname>Vovk</surname><given-names>V.</given-names></name><article-title>A tutorial on conformal prediction</article-title>. <source>J. Machine
Learning Res.</source><year>2008</year>, <volume>9</volume> (<issue>Mar</issue>), <fpage>371</fpage>–<lpage>421</lpage>.</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Santos</surname><given-names>R.</given-names></name>; <name><surname>Ursu</surname><given-names>O.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Donadi</surname><given-names>R. S.</given-names></name>; <name><surname>Bologa</surname><given-names>C. G.</given-names></name>; <name><surname>Karlsson</surname><given-names>A.</given-names></name>; <name><surname>Al-Lazikani</surname><given-names>B.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Oprea</surname><given-names>T. I.</given-names></name>; <name><surname>Overington</surname><given-names>J. P.</given-names></name><article-title>A comprehensive
map of molecular drug targets</article-title>. <source>Nat. Rev. Drug
Discovery</source><year>2017</year>, <volume>16</volume> (<issue>1</issue>), <fpage>19</fpage><pub-id pub-id-type="doi">10.1038/nrd.2016.230</pub-id>.<pub-id pub-id-type="pmid">27910877</pub-id></mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>McGann</surname><given-names>M.</given-names></name><article-title>FRED and HYBRID
docking performance on standardized datasets</article-title>. <source>J. Comput.-Aided Mol. Des.</source><year>2012</year>, <volume>26</volume> (<issue>8</issue>), <fpage>897</fpage>–<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-012-9584-8</pub-id>.<pub-id pub-id-type="pmid">22669221</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Mysinger</surname><given-names>M. M.</given-names></name>; <name><surname>Carchia</surname><given-names>M.</given-names></name>; <name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>Directory of useful
decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking</article-title>. <source>J. Med. Chem.</source><year>2012</year>, <volume>55</volume> (<issue>14</issue>), <fpage>6582</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1021/jm300687e</pub-id>.<pub-id pub-id-type="pmid">22716043</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="computer-program" id="cit23"><person-group><name><surname>Landrum</surname><given-names>G.</given-names></name></person-group><source>Rdkit documentation</source>, Release <year>2013</year>; <volume>1</volume>, <fpage>1</fpage>–<lpage>79</lpage>.</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Hur</surname><given-names>E.</given-names></name>; <name><surname>Pfaff</surname><given-names>S. J.</given-names></name>; <name><surname>Payne</surname><given-names>E. S.</given-names></name>; <name><surname>Grøn</surname><given-names>H.</given-names></name>; <name><surname>Buehrer</surname><given-names>B. M.</given-names></name>; <name><surname>Fletterick</surname><given-names>R. J.</given-names></name><article-title>Recognition and accommodation at
the androgen receptor coactivator binding interface</article-title>. <source>PLoS Biol.</source><year>2004</year>, <volume>2</volume> (<issue>9</issue>), <elocation-id>e274</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0020274</pub-id>.<pub-id pub-id-type="pmid">15328534</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Brzozowski</surname><given-names>A. M.</given-names></name>; <name><surname>Pike</surname><given-names>A. C.</given-names></name>; <name><surname>Dauter</surname><given-names>Z.</given-names></name>; <name><surname>Hubbard</surname><given-names>R. E.</given-names></name>; <name><surname>Bonn</surname><given-names>T.</given-names></name>; <name><surname>Engström</surname><given-names>O.</given-names></name>; <name><surname>Öhman</surname><given-names>L.</given-names></name>; <name><surname>Greene</surname><given-names>G. L.</given-names></name>; <name><surname>Gustafsson</surname><given-names>J.-Å.</given-names></name>; <name><surname>Carlquist</surname><given-names>M.</given-names></name><article-title>Molecular
basis of agonism and antagonism in the oestrogen
receptor</article-title>. <source>Nature</source><year>1997</year>, <volume>389</volume> (<issue>6652</issue>), <fpage>753</fpage><pub-id pub-id-type="doi">10.1038/39645</pub-id>.<pub-id pub-id-type="pmid">9338790</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>van
Marrewijk</surname><given-names>L. M.</given-names></name>; <name><surname>Polyak</surname><given-names>S. W.</given-names></name>; <name><surname>Hijnen</surname><given-names>M.</given-names></name>; <name><surname>Kuruvilla</surname><given-names>D.</given-names></name>; <name><surname>Chang</surname><given-names>M. R.</given-names></name>; <name><surname>Shin</surname><given-names>Y.</given-names></name>; <name><surname>Kamenecka</surname><given-names>T. M.</given-names></name>; <name><surname>Griffin</surname><given-names>P. R.</given-names></name>; <name><surname>Bruning</surname><given-names>J. B.</given-names></name><article-title>SR2067 Reveals a Unique Kinetic and
Structural Signature for PPARgamma Partial Agonism</article-title>. <source>ACS Chem. Biol.</source><year>2016</year>, <volume>11</volume> (<issue>1</issue>), <fpage>273</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.5b00580</pub-id>.<pub-id pub-id-type="pmid">26579553</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Kukimoto-Niino</surname><given-names>M.</given-names></name>; <name><surname>Yoshikawa</surname><given-names>S.</given-names></name>; <name><surname>Takagi</surname><given-names>T.</given-names></name>; <name><surname>Ohsawa</surname><given-names>N.</given-names></name>; <name><surname>Tomabechi</surname><given-names>Y.</given-names></name>; <name><surname>Terada</surname><given-names>T.</given-names></name>; <name><surname>Shirouzu</surname><given-names>M.</given-names></name>; <name><surname>Suzuki</surname><given-names>A.</given-names></name>; <name><surname>Lee</surname><given-names>S.</given-names></name>; <name><surname>Yamauchi</surname><given-names>T.</given-names></name>; <name><surname>Okada-Iwabu</surname><given-names>M.</given-names></name>; <name><surname>Iwabu</surname><given-names>M.</given-names></name>; <name><surname>Kadowaki</surname><given-names>T.</given-names></name>; <name><surname>Minokoshi</surname><given-names>Y.</given-names></name>; <name><surname>Yokoyama</surname><given-names>S.</given-names></name><article-title>Crystal structure of the Ca<sup>2+</sup>/calmodulin-dependent protein kinase kinase in complex with the inhibitor
STO-609</article-title>. <source>J. Biol. Chem.</source><year>2011</year>, <volume>286</volume> (<issue>25</issue>), <fpage>22570</fpage>–<lpage>22579</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.251710</pub-id>.<pub-id pub-id-type="pmid">21504895</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Chen</surname><given-names>P.</given-names></name>; <name><surname>Lee</surname><given-names>N. V.</given-names></name>; <name><surname>Hu</surname><given-names>W.</given-names></name>; <name><surname>Xu</surname><given-names>M.</given-names></name>; <name><surname>Ferre</surname><given-names>R. A.</given-names></name>; <name><surname>Lam</surname><given-names>H.</given-names></name>; <name><surname>Bergqvist</surname><given-names>S.</given-names></name>; <name><surname>Solowiej</surname><given-names>J.</given-names></name>; <name><surname>Diehl</surname><given-names>W.</given-names></name>; <name><surname>He</surname><given-names>Y.-A.</given-names></name>; <name><surname>Yu</surname><given-names>X.</given-names></name>; <name><surname>Nagata</surname><given-names>A.</given-names></name>; <name><surname>VanArsdale</surname><given-names>T.</given-names></name>; <name><surname>Murray</surname><given-names>B. W.</given-names></name><article-title>Spectrum and degree
of CDK drug interactions predicts clinical performance</article-title>. <source>Mol. Cancer Ther.</source><year>2016</year>, <volume>15</volume> (<issue>10</issue>), <fpage>2273</fpage>–<lpage>2281</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0300</pub-id>.<pub-id pub-id-type="pmid">27496135</pub-id></mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>McTigue</surname><given-names>M.</given-names></name>; <name><surname>Murray</surname><given-names>B. W.</given-names></name>; <name><surname>Chen</surname><given-names>J. H.</given-names></name>; <name><surname>Deng</surname><given-names>Y.-L.</given-names></name>; <name><surname>Solowiej</surname><given-names>J.</given-names></name>; <name><surname>Kania</surname><given-names>R. S.</given-names></name><article-title>Molecular conformations,
interactions, and properties
associated with drug efficiency and clinical performance among VEGFR
TK inhibitors</article-title>. <source>Proc. Natl. Acad. Sci. U. S.
A.</source><year>2012</year>, <volume>109</volume> (<issue>45</issue>), <fpage>18281</fpage>–<lpage>18289</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1207759109</pub-id>.<pub-id pub-id-type="pmid">22988103</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Cheng</surname><given-names>R. K.</given-names></name>; <name><surname>Segala</surname><given-names>E.</given-names></name>; <name><surname>Robertson</surname><given-names>N.</given-names></name>; <name><surname>Deflorian</surname><given-names>F.</given-names></name>; <name><surname>Doré</surname><given-names>A. S.</given-names></name>; <name><surname>Errey</surname><given-names>J. C.</given-names></name>; <name><surname>Fiez-Vandal</surname><given-names>C.</given-names></name>; <name><surname>Marshall</surname><given-names>F. H.</given-names></name>; <name><surname>Cooke</surname><given-names>R. M.</given-names></name><article-title>Structures of human A1 and A2A adenosine
receptors with xanthines reveal determinants of selectivity</article-title>. <source>Structure</source><year>2017</year>, <volume>25</volume> (<issue>8</issue>), <fpage>1275</fpage>–<lpage>1285</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2017.06.012</pub-id>.<pub-id pub-id-type="pmid">28712806</pub-id></mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Fan</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>S.</given-names></name>; <name><surname>Yuan</surname><given-names>X.</given-names></name>; <name><surname>Han</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Xia</surname><given-names>W.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Zhao</surname><given-names>Q.</given-names></name>; <name><surname>Wu</surname><given-names>B.</given-names></name><article-title>Structural basis for
ligand recognition of the human thromboxane A 2 receptor</article-title>. <source>Nat. Chem. Biol.</source><year>2019</year>, <volume>15</volume> (<issue>1</issue>), <fpage>27</fpage><pub-id pub-id-type="doi">10.1038/s41589-018-0170-9</pub-id>.<pub-id pub-id-type="pmid">30510189</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Unal</surname><given-names>H.</given-names></name>; <name><surname>Gati</surname><given-names>C.</given-names></name>; <name><surname>Han</surname><given-names>G. W.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Zatsepin</surname><given-names>N. A.</given-names></name>; <name><surname>James</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>; <name><surname>Nelson</surname><given-names>G.</given-names></name>; <name><surname>Weierstall</surname><given-names>U.</given-names></name>; <name><surname>Sawaya</surname><given-names>M. R.</given-names></name>; <name><surname>Xu</surname><given-names>Q.</given-names></name>; <name><surname>Messerschmidt</surname><given-names>M.</given-names></name>; <name><surname>Williams</surname><given-names>G. J.</given-names></name>; <name><surname>Boutet</surname><given-names>S.</given-names></name>; <name><surname>Yefanov</surname><given-names>O. M.</given-names></name>; <name><surname>White</surname><given-names>T. A.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Ishchenko</surname><given-names>A.</given-names></name>; <name><surname>Tirupula</surname><given-names>K. C.</given-names></name>; <name><surname>Desnoyer</surname><given-names>R.</given-names></name>; <name><surname>Coe</surname><given-names>J.</given-names></name>; <name><surname>Conrad</surname><given-names>C. E.</given-names></name>; <name><surname>Fromme</surname><given-names>P.</given-names></name>; <name><surname>Stevens</surname><given-names>R. C.</given-names></name>; <name><surname>Katritch</surname><given-names>V.</given-names></name>; <name><surname>Karnik</surname><given-names>S. S.</given-names></name>; <name><surname>Cherezov</surname><given-names>V.</given-names></name><article-title>Structure of the Angiotensin receptor
revealed by serial femtosecond crystallography</article-title>. <source>Cell</source><year>2015</year>, <volume>161</volume> (<issue>4</issue>), <fpage>833</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.04.011</pub-id>.<pub-id pub-id-type="pmid">25913193</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Ahuja</surname><given-names>S.</given-names></name>; <name><surname>Mukund</surname><given-names>S.</given-names></name>; <name><surname>Deng</surname><given-names>L.</given-names></name>; <name><surname>Khakh</surname><given-names>K.</given-names></name>; <name><surname>Chang</surname><given-names>E.</given-names></name>; <name><surname>Ho</surname><given-names>H.</given-names></name>; <name><surname>Shriver</surname><given-names>S.</given-names></name>; <name><surname>Young</surname><given-names>C.</given-names></name>; <name><surname>Lin</surname><given-names>S.</given-names></name>; <name><surname>Johnson</surname><given-names>J.</given-names></name><article-title>Structural
basis of Nav1. 7 inhibition by an isoform-selective small-molecule
antagonist</article-title>. <source>Science</source><year>2015</year>, <volume>350</volume> (<issue>6267</issue>), <elocation-id>aac5464</elocation-id><pub-id pub-id-type="doi">10.1126/science.aac5464</pub-id>.<pub-id pub-id-type="pmid">26680203</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Pan</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>Q.</given-names></name>; <name><surname>Willenbring</surname><given-names>D.</given-names></name>; <name><surname>Mowrey</surname><given-names>D.</given-names></name>; <name><surname>Kong</surname><given-names>X.-P.</given-names></name>; <name><surname>Cohen</surname><given-names>A.</given-names></name>; <name><surname>Divito</surname><given-names>C. B.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Tang</surname><given-names>P.</given-names></name><article-title>Structure
of the pentameric ligand-gated ion channel GLIC bound with anesthetic
ketamine</article-title>. <source>Structure</source><year>2012</year>, <volume>20</volume> (<issue>9</issue>), <fpage>1463</fpage>–<lpage>1469</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2012.08.009</pub-id>.<pub-id pub-id-type="pmid">22958642</pub-id></mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Zhu</surname><given-names>S.</given-names></name>; <name><surname>Noviello</surname><given-names>C. M.</given-names></name>; <name><surname>Teng</surname><given-names>J.</given-names></name>; <name><surname>Walsh</surname><given-names>R. M.</given-names><suffix>jr</suffix></name>; <name><surname>Kim</surname><given-names>J. J.</given-names></name>; <name><surname>Hibbs</surname><given-names>R. E.</given-names></name><article-title>Structure
of a human synaptic GABAA
receptor</article-title>. <source>Nature</source><year>2018</year>, <volume>559</volume> (<issue>7712</issue>), <fpage>67</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-018-0255-3</pub-id>.<pub-id pub-id-type="pmid">29950725</pub-id></mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Sussman</surname><given-names>J. L.</given-names></name>; <name><surname>Lin</surname><given-names>D.</given-names></name>; <name><surname>Jiang</surname><given-names>J.</given-names></name>; <name><surname>Manning</surname><given-names>N. O.</given-names></name>; <name><surname>Prilusky</surname><given-names>J.</given-names></name>; <name><surname>Ritter</surname><given-names>O.</given-names></name>; <name><surname>Abola</surname><given-names>E. E.</given-names></name><article-title>Protein
Data Bank (PDB): database of three-dimensional
structural information of biological macromolecules</article-title>. <source>Acta Crystallogr., Sect. D: Biol. Crystallogr.</source><year>1998</year>, <volume>54</volume> (<issue>6</issue>), <fpage>1078</fpage>–<lpage>1084</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444998009378</pub-id>.<pub-id pub-id-type="pmid">10089483</pub-id></mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="computer-program" id="cit37"><source>Schrödinger
Release 2019-3: Maestro</source>; <publisher-name>Schrödinger,
LLC</publisher-name>: <publisher-loc>New York,
NY, USA</publisher-loc> ,<year>2019</year>.</mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="computer-program" id="cit38"><source>OEDOCKING 3.3.1.2</source>; <publisher-name>OpenEye Scientific
Software</publisher-name>: <publisher-loc>Santa Fe, NM, USA</publisher-loc>, <year>2019</year>.</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="journal" id="cit39"><name><surname>Hawkins</surname><given-names>P.
C.</given-names></name>; <name><surname>Skillman</surname><given-names>A. G.</given-names></name>; <name><surname>Warren</surname><given-names>G. L.</given-names></name>; <name><surname>Ellingson</surname><given-names>B. A.</given-names></name>; <name><surname>Stahl</surname><given-names>M. T.</given-names></name><article-title>Conformer generation
with OMEGA: algorithm and validation
using high quality structures from the Protein Databank and Cambridge
Structural Database</article-title>. <source>J. Chem. Inf. Model.</source><year>2010</year>, <volume>50</volume> (<issue>4</issue>), <fpage>572</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1021/ci100031x</pub-id>.<pub-id pub-id-type="pmid">20235588</pub-id></mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="computer-program" id="cit40"><person-group person-group-type="allauthors"><name><surname>Hawkins</surname><given-names>P.</given-names></name>; <name><surname>Skillman</surname><given-names>A.</given-names></name>; <name><surname>Warren</surname><given-names>G.</given-names></name>; <name><surname>Ellingson</surname><given-names>B.</given-names></name>; <name><surname>Stahl</surname><given-names>M.</given-names></name></person-group><source>OMEGA 3.1.0.3</source>, <year>2019</year>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="computer-program" id="cit41"><person-group person-group-type="allauthors"><name><surname>Chollet</surname><given-names>F.</given-names></name></person-group><source>Keras</source>, <year>2015</year>.</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="journal" id="cit42"><name><surname>Svozil</surname><given-names>D.</given-names></name>; <name><surname>Kvasnicka</surname><given-names>V.</given-names></name>; <name><surname>Pospichal</surname><given-names>J.</given-names></name><article-title>Introduction to multi-layer feed-forward
neural networks</article-title>. <source>Chemom. Intell. Lab. Syst.</source><year>1997</year>, <volume>39</volume> (<issue>1</issue>), <fpage>43</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-7439(97)00061-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name><article-title>A discussion of measures of enrichment in virtual screening:
comparing the information content of descriptors with increasing levels
of sophistication</article-title>. <source>J. Chem. Inf. Model.</source><year>2005</year>, <volume>45</volume> (<issue>5</issue>), <fpage>1369</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1021/ci0500177</pub-id>.<pub-id pub-id-type="pmid">16180913</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
